Vandetanib in Advanced NSCLC With RET Rearrangement

NCT01823068 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Vandetanib

Sponsor

Samsung Medical Center

Collaborators

[object Object]